| View printer-friendly version|
Organovo Celebrates Economist Technology Quarterly Coverage
In its coverage, the Economist's Technology Quarterly describes:
- the role of Organovo Scientific Founder Prof. Gabor Forgacs in foundational work in the bioprinting field;
- the potential of
Organovo'sbioprinted 3D Liver tissues to improve pharmaceutical toxicity testing; Organovo'stechnology advantage in being able to make 100% cellular tissues; and Organovo'swork in early animal studies to create simple tissues for direct surgical implantation to treat patients; and other details of the company's strategy, technology, and operations.
In putting together their detailed coverage, the Economist's Technology Quarterly had a scientific writer visit the company, receive access to the company's facilities, and review and interview many others in the space.
As regards certain other information outlets,
While some errors may be unintentional or simply sloppy, on some occasions it is possible that some authors may be following a "Short and Distort" strategy, where they purposefully create a negative picture after taking a short position.
- Use phrases like "Trading Warning" or "Urgent" explicitly intended to cause fear and based on no new publicly released information about the Company;
- Be written by a person with a short position and focused on negative details – with little balanced discussion of positives and negatives about the Company;
- Be written by an individual with no known track record in investing or equity analysis, no known scientific qualifications, or in fact no affiliation with any entity known to the investor which could provide any confidence in his or her qualifications;
- Pretend to have a greater understanding of
Organovo's SECfilings, especially in regards to potential future financings or share registrations, and proceed to interpret them selectively in unbalanced ways;
- Be excessively focused on
Organovo'spath to becoming public through reverse merger, ignoring the fact that the company's subsequent fully underwritten secondary offering at > $40M, with full investment bank diligence, removes consideration of Organovounder the typical reverse merger listing standards by both NYSEand NASDAQ;
Organovo'slack of current revenue as somehow indicative of the promise of its future products rather than its status as a development stage biotechnology company;
- Highlight and demonize the potential for future financing instead of recognizing it as beneficial for shareholders under the right conditions;
- Focus on
Organovo'sinstitutional investor holdings without noting that these holdings have grown significantly since early 2013, or without noting that the company conducted a financing round in August 2013that consisted nearly entirely of seasoned institutional biotech investment funds;
- Cherry pick negative details for past companies where
Organovoexecutives played roles, without discussion of the multiple successful roles the same executives have played in companies acquired for nine-figure sums, or their participation in product development for products and product lines currently generating revenue in the billions of dollars;
Organovo'spublic company executive salaries, including non-founders, to private startup founders for earlier stage companies rather than peer companies;
Organovo'spartnerships or doubt their existence – when review of all of the company's relationships with these groups, including reviewing full contract detail and conducting direct discussions with the partner companies, is performed by investment bankers as part of diligence for underwritten deals such as Organovo'ssale of securities on August 1, 2013;
- Refer to an EnvisionTEC Bioplotter that prints biomaterials suitable for scaffolds as a "bioprinter", and compare it to bioprinting instruments designed to create living human tissue from cellular inks; or
- Refer to other
Organovoshort thesis article sources as if they were excellent points of reference (e.g., cross referencing other writers on the same website, referring to Nanalyze, or even pointing to the personally maintained webpage of an "online commentator" whose sole previous qualification and experience in analysis is literally writing comments on websites).
The company would like to help investors judge such content appropriately, and point out the risks of encountering false information. The company would like to stress that in providing information in regards to such sites or reports to investors, it is not claiming that all articles with a negative connotation are false. In addition, not every positive article regarding the company may be balanced with the potential risks and uncertainties the company faces. For these reasons,
The company reminds investors to review its
The company reminds investors that its FAQ pages are regularly updated and an excellent source of information. Click here to read the current FAQ.
In addition, the company regularly engages investors in public forums to answer questions and discuss the sorts of issues of concern to investors. Please watch
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the